Review Article                                     
Article download: 114

 

Crossmark logo
 

Hypoxia-Induced Intestinal Cellular Injury: Molecular Adaptations and Clinical Significance

Mehmet Arslan, MD, PhD1, Ayşe Demir, MD 2* ORCID 

1Department of Gastroenterology, Faculty of Medicine, Hacettepe University, Ankara, Türkiye.
2Department of Internal Medicine, Division of Gastroenterology, İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye.

DOI: 10.18081/2378-5225/12.1  
Cited by 0

 Article history: Received 13, October 2022 · Revised 13, December 2022 · Accepted 11, January 2023 · Published 29, January 2023

© 2024 Bennett, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0). 

CC BY 4.0                                                                                                   

Abstract

The intestinal mucosa exists within a unique physiological oxygen gradient that is essential for maintaining epithelial homeostasis, barrier integrity, immune surveillance, and host–microbiota interactions. Although physiological hypoxia is a normal feature of the intestinal microenvironment, sustained or severe oxygen deprivation initiates a complex cascade of molecular and cellular events that culminate in intestinal epithelial injury and contribute to the pathogenesis of numerous gastrointestinal and systemic disorders. Growing evidence has identified hypoxia as a central driver of intestinal ischemia–reperfusion injury, inflammatory bowel disease, necrotizing enterocolitis, radiation enteropathy, sepsis-associated intestinal dysfunction, and colorectal tumorigenesis. Recent advances in molecular biology have substantially expanded current understanding of the signaling pathways governing hypoxic adaptation and their implications for disease progression and therapeutic intervention. This review provides a comprehensive synthesis of the current evidence regarding the molecular mechanisms underlying hypoxia-induced intestinal cellular injury, emphasizing oxygen-sensing pathways, metabolic reprogramming, mitochondrial dysfunction, oxidative stress, inflammatory signaling, epithelial barrier disruption, and regulated cell death. Particular attention is given to the central role of hypoxia-inducible factors (HIFs), prolyl hydroxylase domain enzymes, AMP-activated protein kinase, mammalian target of rapamycin, and nuclear factor erythroid 2-related factor 2 in coordinating adaptive and maladaptive cellular responses to oxygen deprivation. Furthermore, the review discusses the reciprocal interactions among epithelial cells, immune cells, endothelial cells, and the intestinal microbiota that collectively determine mucosal homeostasis or disease progression under hypoxic conditions. Emerging evidence indicates that prolonged hypoxia promotes mitochondrial dysfunction, excessive reactive oxygen species generation, endoplasmic reticulum stress, inflammasome activation, and disruption of epithelial tight junctions, leading to increased intestinal permeability and amplification of local and systemic inflammatory responses. Concurrent activation of apoptosis, necroptosis, pyroptosis, ferroptosis, and dysregulated autophagy further accelerates epithelial injury and compromises mucosal repair. Advances in single-cell transcriptomics, spatial omics, metabolomics, and artificial intelligence-assisted data analysis are simultaneously improving understanding of intestinal hypoxia while facilitating the discovery of novel biomarkers and therapeutic targets. Pharmacological modulation of HIF signaling, mitochondrial protection, antioxidant defense, epithelial regeneration, microbiome-based therapies, and precision medicine approaches represent promising strategies for mitigating hypoxia-associated intestinal injury.
Conclusion: Hypoxia-induced intestinal cellular injury represents a complex, multifactorial process involving tightly interconnected metabolic, mitochondrial, inflammatory, and immune regulatory networks. Improved understanding of oxygen-sensing mechanisms and epithelial adaptive responses has transformed the conceptual framework of intestinal injury and identified numerous opportunities for targeted therapeutic intervention. Future integration of single-cell sequencing, spatial transcriptomics, artificial intelligence, and multi-omics technologies is expected to accelerate biomarker discovery, refine patient stratification, and facilitate precision medicine approaches for the prevention and treatment of hypoxia-associated intestinal diseases.

Keywords: intestinal hypoxia; intestinal epithelial injury; hypoxia-inducible factor; mitochondrial dysfunction; oxidative stress.

References

  1. Colgan SP, Taylor CT. Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol. 2010;7(5):281-287. doi:10.1038/nrgastro.2010.39
  2. Taylor CT, Colgan SP. Regulation of immunity and inflammation by hypoxia in immunological niches. Nat Rev Immunol. 2017;17(12):774-785. doi:10.1038/nri.2017.103
  3. Singhal R, Shah YM. Oxygen battle in the gut: hypoxia and hypoxia-inducible factors in metabolic and inflammatory responses in the intestine. J Biol Chem. 2020;295(30):10493-10505. doi:10.1074/jbc.REV120.011188
  4. Konjar Š, Pavšič M, Veldhoen M. Regulation of oxygen homeostasis at the intestinal epithelial barrier site. Int J Mol Sci. 2021;22(17):9170. doi:10.3390/ijms22179170
  5. Pral LP, Fachi JL, Corrêa RO, Colonna M, Vinolo MAR. Hypoxia and HIF-1 as key regulators of gut microbiota and host interactions. Trends Immunol. 2021;42(7):604-621. doi:10.1016/j.it.2021.05.004
  6. Dvornikova KA, Bystrova EY, Platonova ON, Churilov LP. Hypoxia and intestinal inflammation: common molecular mechanisms and implications for inflammatory bowel disease. Int J Mol Sci. 2023;24(3):2425. doi:10.3390/ijms24032425
  7. Shah YM. The role of hypoxia in intestinal inflammation. Mol Cell Pediatr. 2016;3(1):1. doi:10.1186/s40348-016-0030-1
  8. Glover LE, Lee JS, Colgan SP. Oxygen metabolism and barrier regulation in the intestinal mucosa. J Clin Invest. 2016;126(10):3680-3688. doi:10.1172/JCI84429
  9. Glover LE, Colgan SP. Epithelial barrier regulation by hypoxia-inducible factor. Ann Am Thorac Soc. 2017;14(suppl 3):S233-S236. doi:10.1513/AnnalsATS.201609-714AW
  10. Steiner CA, Ehlers H, Swaggerty CL, et al. Hypoxia-inducible factor as a bridge between healthy barrier function, wound healing, and fibrosis. Am J Physiol Cell Physiol. 2022;323(3):C866-C878. doi:10.1152/ajpcell.00227.2022
  11. Furuta GT, Turner JR, Taylor CT, et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J Exp Med. 2001;193(9):1027-1034. doi:10.1084/jem.193.9.1027
  12. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SP, Haase VH. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest. 2004;114(8):1098-1106. doi:10.1172/JCI21086
  13. Cummins EP, Seeballuck F, Keely SJ, et al. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology. 2008;134(1):156-165. doi:10.1053/j.gastro.2007.10.012
  14. Robinson A, Keely S, Karhausen J, Gerich ME, Furuta GT, Colgan SP. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology. 2008;134(1):145-155. doi:10.1053/j.gastro.2007.09.033
  15. Tambuwala MM, Cummins EP, Lenihan CR, et al. Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology. 2010;139(6):2093-2101. doi:10.1053/j.gastro.2010.06.068
  16. Keely S, Campbell EL, Baird AW, et al. Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis. Mucosal Immunol. 2014;7(1):114-123. doi:10.1038/mi.2013.29
  17. Manresa MC, Taylor CT. Hypoxia-inducible factor hydroxylases as regulators of intestinal epithelial barrier function. Cell Mol Gastroenterol Hepatol. 2017;3(3):303-315. doi:10.1016/j.jcmgh.2017.02.004
  18. Ramakrishnan SK, Shah YM. Role of intestinal HIF-2α in health and disease. Annu Rev Physiol. 2016;78:301-325. doi:10.1146/annurev-physiol-021115-105202
  19. Xue X, Ramakrishnan SK, Shah YM. Activation of HIF-1α does not increase intestinal tumorigenesis. Am J Physiol Gastrointest Liver Physiol. 2014;307(2):G187-G195. doi:10.1152/ajpgi.00112.2014
  20. Xue X, Ramakrishnan S, Anderson E, et al. Endothelial PAS domain protein 1 activates the inflammatory response in the intestinal epithelium to promote colitis in mice. Gastroenterology. 2013;145(4):831-841. doi:10.1053/j.gastro.2013.07.010
  21. Solanki S, Devenport SN, Ramakrishnan SK, Shah YM. Temporal induction of intestinal epithelial hypoxia-inducible factor-2α is sufficient to drive colitis. Am J Physiol Gastrointest Liver Physiol. 2019;317(2):G98-G107. doi:10.1152/ajpgi.00097.2019
  22. Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe. 2015;17(5):662-671. doi:10.1016/j.chom.2015.03.005
  23. Byndloss MX, Olsan EE, Rivera-Chávez F, et al. Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion. Science. 2017;357(6351):570-575. doi:10.1126/science.aam9949
  24. Rivera-Chávez F, Zhang LF, Faber F, et al. Depletion of butyrate-producing Clostridia from the gut microbiota drives an aerobic luminal expansion of Salmonella. Cell Host Microbe. 2016;19(4):443-454. doi:10.1016/j.chom.2016.03.004
  25. Litvak Y, Byndloss MX, Bäumler AJ. Colonocyte metabolism shapes the gut microbiota. Science. 2018;362(6418):eaat9076. doi:10.1126/science.aat9076
  26. Zheng L, Kelly CJ, Battista KD, et al. Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2. J Immunol. 2017;199(8):2976-2984. doi:10.4049/jimmunol.1700105
  27. Zhou C, Li L, Li T, et al. SCFAs induce autophagy in intestinal epithelial cells and relieve colitis by stabilizing HIF-1α. J Mol Med (Berl). 2020;98(8):1189-1202. doi:10.1007/s00109-020-01947-2
  28. Colgan SP, Curtis VF, Campbell EL. The inflammatory tissue microenvironment in IBD. Inflamm Bowel Dis. 2013;19(10):2238-2244. doi:10.1097/MIB.0b013e31828dcaaf
  29. Colgan SP, Campbell EL, Kominsky DJ. Hypoxia and mucosal inflammation. Annu Rev Pathol. 2016;11:77-100. doi:10.1146/annurev-pathol-012615-044231
  30. Campbell EL, Colgan SP. Control and dysregulation of redox signalling in the gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2019;16(2):106-120. doi:10.1038/s41575-018-0079-5
  31. Li G, Wang S, Fan Z. Oxidative stress in intestinal ischemia-reperfusion. Front Med (Lausanne). 2021;8:750731. doi:10.3389/fmed.2021.750731
  32. Mallick IH, Yang W, Winslet MC, Seifalian AM. Ischemia-reperfusion injury of the intestine and protective strategies against injury. Dig Dis Sci. 2004;49(9):1359-1377. doi:10.1023/B:DDAS.0000042232.98927.91
  33. Vollmar B, Menger MD. Intestinal ischemia/reperfusion: microcirculatory pathology and functional consequences. Langenbecks Arch Surg. 2011;396(1):13-29. doi:10.1007/s00423-010-0727-x
  34. Grootjans J, Lenaerts K, Derikx JPM, et al. Human intestinal ischemia-reperfusion-induced inflammation characterized by rapid neutrophil activation. Am J Pathol. 2010;176(5):2283-2291. doi:10.2353/ajpath.2010.091154
  35. Grootjans J, Thuijls G, Verdam F, Derikx JPM, Lenaerts K, Buurman WA. Noninvasive assessment of barrier integrity and function of the human gut. World J Gastrointest Surg. 2010;2(3):61-69. doi:10.4240/wjgs.v2.i3.61
  36. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol. 2012;298:229-317. doi:10.1016/B978-0-12-394309-5.00006-7
  37. Eltzschig HK, Eckle T. Ischemia and reperfusion—from mechanism to translation. Nat Med. 2011;17(11):1391-1401. doi:10.1038/nm.2507
  38. Chouchani ET, Pell VR, Gaude E, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515(7527):431-435. doi:10.1038/nature13909
  39. Hu Q, Ren J, Li G, et al. The mitochondrially targeted antioxidant MitoQ protects the intestinal barrier by ameliorating mitochondrial DNA damage during intestinal ischemia-reperfusion. J Cell Physiol. 2018;233(8):6126-6137. doi:10.1002/jcp.26459
  40. Hu Q, Ren J, Wu J, et al. Elevated levels of plasma mitochondrial DNA are associated with clinical outcome in intra-abdominal infections caused by severe trauma. Surg Infect (Larchmt). 2017;18(5):610-618. doi:10.1089/sur.2016.276
  41. Liao S, Luo J, Kadier T, Ding K, Chen R, Meng Q. Mitochondrial DNA release contributes to intestinal ischemia-reperfusion injury. Front Pharmacol. 2022;13:854994. doi:10.3389/fphar.2022.854994
  42. Hu Q, Ren J, Li G, et al. Released mitochondrial DNA following intestinal ischemia reperfusion induces the inflammatory response and gut barrier dysfunction. Sci Rep. 2018;8(1):7350. doi:10.1038/s41598-018-25387-8
  43. Günther C, Neumann H, Neurath MF, Becker C. Apoptosis, necrosis and necroptosis: cell death regulation in the intestinal epithelium. Gut. 2013;62(7):1062-1071. doi:10.1136/gutjnl-2011-301364
  44. Günther C, Martini E, Wittkopf N, et al. Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature. 2011;477(7364):335-339. doi:10.1038/nature10400
  45. Welz PS, Wullaert A, Vlantis K, et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature. 2011;477(7364):330-334. doi:10.1038/nature10273
  46. Subramanian S, Geng H, Tan XD. Cell death of intestinal epithelial cells in intestinal diseases. Sheng Li Xue Bao. 2020;72(3):308-324.
  47. Rathinam VAK, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. Cell. 2016;165(4):792-800. doi:10.1016/j.cell.2016.03.046
  48. Man SM, Kanneganti TD. Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nat Rev Immunol. 2016;16(1):7-21. doi:10.1038/nri.2015.7
  49. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060-1072. doi:10.1016/j.cell.2012.03.042
  50. Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273-285. doi:10.1016/j.cell.2017.09.021
  51. Xu S, He Y, Lin L, Chen P, Chen M, Zhang S. The emerging role of ferroptosis in intestinal disease. Cell Death Dis. 2021;12(4):289. doi:10.1038/s41419-021-03559-1
  52. Zhang X, Zhang P, An L, et al. Ferroptosis as a therapeutic target for inflammation-related intestinal diseases. Front Pharmacol. 2023;14:1095366. doi:10.3389/fphar.2023.1095366
  53. Wang F, Yang YJ, Yang N, et al. Targeting cell death pathways in intestinal ischemia-reperfusion injury: from molecular mechanisms to therapeutic implications. Cell Death Discov. 2024;10(1):91. doi:10.1038/s41420-024-01855-3
  54. Derikx JPM, Luyer MDP, Heineman E, Buurman WA. Noninvasive markers of gut wall integrity in health and disease. World J Gastroenterol. 2010;16(42):5272-5279. doi:10.3748/wjg.v16.i42.5272
  55. Yousif NG, Hadi N, Zigam Q, Al-Amran FG. Cardioprotective effects of irbesartan in polymicrobial sepsis. 2018:140-145. https://doi.org/10.1007/s00059-017-4537-6
  56. Blaser AR, Kals J, Starkopf J, Deane AM, Poeze M, Starkopf L. Citrulline and intestinal fatty acid-binding protein as biomarkers for gastrointestinal dysfunction in the critically ill. Anaesthesiol Intensive Ther. 2019;51(3):230-239. doi:10.5114/ait.2019.86049
  57. Thuijls G, van Wijck K, Grootjans J, et al. Early diagnosis of intestinal ischemia using urinary and plasma fatty acid-binding proteins. Ann Surg. 2011;253(2):303-308. doi:10.1097/SLA.0b013e318207a767
  58. Schellekens DHSM, Grootjans J, Dello SAWG, et al. Plasma intestinal fatty acid-binding protein levels correlate with morphologic epithelial intestinal damage in a human translational ischemia-reperfusion model. J Clin Gastroenterol. 2014;48(3):253-260. doi:10.1097/MCG.0b013e3182a87e3e
  59. Kim YI, Yi EJ, Kim YD, et al. Local stabilization of hypoxia-inducible factor-1α controls intestinal inflammation via enhanced gut barrier function and immune regulation. Front Immunol. 2021;11:609689. doi:10.3389/fimmu.2020.609689

BM-Publisher · Pathophysiology of Cell Injury Journal (PCIJ) · E-ISSN 2378-5225 · DOI Prefix 10.18081/pcij/2378-5225

Pathophysiology of Cell Injury Journal (PCIJ)
E-ISSN 2378-5225 · Biannual
BM-Publisher (London, UK)
Open Access

Vol 12, Issue 1 (January 2023), pp. 1–20

Download article

PDF
XML

How to cite (AMA)

Arslan, Demir A. Hypoxia-Induced Intestinal Cellular Injury: Molecular Adaptations and Clinical Significance. Pathophysiology of Cell Injury Journal (PCIJ). 2023;12(1):1–20. doi: 10.18081/2378-5225/12.1.

More citation

(2023). . Pathophysiology of Cell Injury Journal (PCIJ), . https://pcij.net/archives/2663
. \".\" Pathophysiology of Cell Injury Journal (PCIJ), 2023, pp. . https://pcij.net/archives/2663
. . Pathophysiology of Cell Injury Journal (PCIJ). 2023;:. https://pcij.net/archives/2663
(2023) . Pathophysiology of Cell Injury Journal (PCIJ), , pp. . Available at: https://pcij.net/archives/2663
@article{2023, title = {}, journal = {Pathophysiology of Cell Injury Journal (PCIJ)}, year = {2023}, url = {https://pcij.net/archives/2663}, }
TY - JOUR TI - JO - Pathophysiology of Cell Injury Journal (PCIJ) PY - 2023 UR - https://pcij.net/archives/2663 ER -

PlumX Metrics